Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada.
Division of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada.
Int J Mol Sci. 2021 Feb 22;22(4):2155. doi: 10.3390/ijms22042155.
The treatment of lung infection in the context of cystic fibrosis (CF) is limited by a biofilm mode of growth of pathogenic organisms. When compared to planktonically grown bacteria, bacterial biofilms can survive extremely high levels of antimicrobials. Within the lung, bacterial biofilms are aggregates of microorganisms suspended in a matrix of self-secreted proteins within the sputum. These structures offer both physical protection from antibiotics as well as a heterogeneous population of metabolically and phenotypically distinct bacteria. The bacteria themselves and the components of the extracellular matrix, in addition to the signaling pathways that direct their behaviour, are all potential targets for therapeutic intervention discussed in this review. This review touches on the successes and failures of current anti-biofilm strategies, before looking at emerging therapies and the mechanisms by which it is hoped they will overcome current limitations.
囊性纤维化（CF）肺部感染的治疗受到致病生物体生物膜生长模式的限制。与浮游生长的细菌相比，细菌生物膜可以在极高水平的抗生素下存活。在肺部，细菌生物膜是微生物在痰中自身分泌的蛋白质基质中悬浮的聚集体。这些结构不仅为抗生素提供了物理保护，还为代谢和表型不同的细菌提供了异质群体。在本综述中讨论了细菌本身和细胞外基质的成分，以及指导其行为的信号通路，都是治疗干预的潜在靶点。这篇综述首先探讨了当前抗生物膜策略的成败，然后研究了新兴疗法以及希望它们克服当前局限性的机制。
